Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of Vertex have increased 35.78% over the past quarter, and have gained 80.42% in the last ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth ...

Cell tower in North Hampton is eagerly awaited by many who hope it will significantly improve the numerous areas with poor ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with ...

William Blair analyst Jake Roberge has maintained their bullish stance on VERX stock, giving a Buy rating today. Jake Roberge has given his ...

This company selected Vertex in part due to Systax as they have extensive operations in Brazil. In addition, we had a strong ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately ... While media releases or rumors about a substantial change in a company's business prospects usually ...